2024 Updates in Thrombosis & Hemostasis

Sunday, October 27, 2024, 9:00 AM - 3:00 PM, Zuckerman Research Center, New York, NY

This symposium aims to deliver the latest updates in benign hematology, with a special emphasis on venous thromboembolism and anticoagulation. The 2024 program will focus on three main areas:

• Current challenges in Venous Thromboembolism (VTE)
• Novel anticoagulants
• Thrombotic complications of clonal disorders

Key topics will include thrombophilia testing, the role of interventional radiology in VTE management, and challenging scenarios such as chronic thromboembolic pulmonary hypertension (CTEPH), refractory thrombosis, and splanchnic thrombosis. Additionally, faculty will review the reversal of direct oral anticoagulants, novel factor XI inhibitors, and unique challenges in the management of thrombosis and clonal disorders (e.g., PNH and myeloproliferative neoplasm). Ample time will be allocated for Q&A and discussions with the faculty.

The target audience includes general medicine practitioners, hematologists/oncologists, intensivists, emergency medicine practitioners, primary care physicians, residents, fellows, advanced practice providers, and other healthcare professionals involved in the management and treatment of thrombotic and bleeding disorders. Additionally, we’re pleased to offer complimentary registration for patients, advocates, and caregivers to attend this program (please see registration details below).

This symposium will be an exclusively in-person event, with no virtual attendance option available. Registered attendees will receive access to an online syllabus after the symposium, which will include select PDFs of the faculty presentations (slides) and recorded videos.

1. Provide guidance and updates on management of challenging thrombotic conditions including indications for thrombophilia testing, role of interventional radiology, management of refractory thrombosis, PNH, and anticoagulation in brain tumors.
2. Summarize recent data on management of anticoagulant related hemorrhage and discuss emerging FXI inhibitors and their potential for improved safety profiles.
3. Recognize the challenges in managing thrombo-hemorrhagic risks in patients with myeloproliferative neoplasms.

Included in registration, attendees will be offered continental breakfast, lunch, and refreshment breaks. Please contact [email protected] at least one week prior to the course if you have any special dietary requests or require any specific accommodations for joining us onsite.

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

• General Rates
  • Physicians (MDs, PhDs, and DOs): $300
  • Advanced Practice Providers: $250
  • Nursing and Other Healthcare Professionals: $200
  • Residents, Fellows, and Students: $100 (non-refundable)
  • Industry Professionals*: $525
  • MSK Employees: Complimentary
  • Patients, Advocates, and Caregivers: Complimentary; Requests can be submitted here.

For details on our cancellation terms, please review our Cancellation Policy.

*An “industry professional” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. View our Registration Policy for Industry Professionals for more information.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 4.50 Medical Knowledge MOC Points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification Assessment Recognition program; and
• 4.50 Lifelong Learning (CME) credit towards the American Board of Pathology’s (ABPath) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC credit.

MOC/CC points will be reported to your board within 45 days upon completion of the course.

ANCC CNE Statement

Memorial Sloan Kettering Cancer Center–Nursing Professional Development / Continuing Education is accredited with distinction as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center’s Commission on Accreditation.

4.75 contact hours will be awarded to participants who attend the program in its entirety and complete a program evaluation. Partial credit not awarded.

Hotel Accommodations

We look forward to welcoming you to Memorial Sloan Kettering for this program. If you’ll be traveling to New York City from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, Memorial Sloan Kettering has negotiated special rates and amenities at select hotels in Manhattan. To view the list of select hotels and additional details on each, please visit: msk.org/accommodations

Parking Information

Street parking in Manhattan is extremely limited, so you may find it more convenient to park in Memorial Sloan Kettering’s garage or in a commercial garage. For a list of parking resources around MSK, click here. Please note that MSK CME does not offer parking validation for course attendees.

MSK Symposium Director

Jeffrey Zwicker, MD
Chief, Hematology Service



MSK Symposium Co-Director 

Rekha Parameswaran, MD
Attending, Hematology Service 



MSK Symposium Planning Committee

Kuo-Kai Chin, MD
Hematology-Oncology Chief Fellow

Avi Leader, MD
Assistant Attending, Hematology Service 

Jodi V. Mones, MD
Associate Program Director, Medical Oncology/Hematology Fellowship, Hematology Track;
Associate Attending, Hematology Service 

Michael Philbin, PhD
Patient Planner

Cara Scotti, PA
Advanced Practice Provider

Cy R. Wilkins, MD
Assistant Attending, Hematology Service 

 

Symposium Invited Faculty 

Kenneth A. Bauer, MD
Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center

Evelyn M. Horn, MD
Director, Perkin Heart Failure Center
Advanced Heart Failure & Pulmonary Vascular Disease Programs
Professor of Clinical Medicine, Weill Cornell
Adjunct Professor, Columbia University
Weill Cornell Medicine

Peter L. Gross, MD
Associate Professor
University of Toronto

Rushad Patell, MD
Assistant Professor of Medicine
Beth Israel Deaconess Medical Center

Deborah Siegal, MD, MSc, FRCPC 
Associate Professor, Department of Medicine and School of Epidemiology and Public Health, University of Ottawa
Scientist, Ottawa Hospital Research Institute

 

MSK Symposium Faculty 

Yolanda Bryce, MD
Assistant Attending, Interventional Radiology Service

Maly Fenelus, MD, MPH
Assistant Director, Clinical Hematology Laboratories;
Director, MSK Nassau Clinical Laboratory;
Assistant Attending
Department of Pathology and Laboratory Medicine

Ioanna Kosmidou, MD
Associate Attending, Cardiology Service

Raajit K. Rampal, MD, PhD
Director, Center for Hematologic Malignancies;
Director, Myeloproliferative Neoplasms Program;
Associate Attending, Leukemia Service

Jessica A. Wilcox, MD
Assistant Attending, Brain Tumor Service

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Sunday, October 27, 2024

Memorial Sloan Kettering Cancer Center is pleased to announce that the following companies will be exhibiting during this symposium:

Agios
National Blood Clot Alliance
Regeneron Pharmaceuticals, Inc.